Three antibodies from Atlas Antibodies in Immuno Oncology - Hodgkin lymphoma research
Article: "CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2"
Image credit: Veldman et al. OncoImmunology 2020
Immuno Oncology: Hodgkin lymphoma
CD4+ cells are a type of T-cell in the immune system that play a critical role in the pathogenesis of classical Hodgkin lymphoma (cHL), a cancer of the lymphatic system.
Veldman et al. (2020) aimed to further characterize the CD4+ T-cells and the protein expression profile in the cHL tumor microenvironment; to this end, immunohistochemistry was performed on 19 cHL tissue samples.
Three antibodies from Atlas Antibodies were used in the study:
anti-TOX2 (HPA049900)
anti-NFIA (HPA006111)
anti-CTTN (HPA057242)
Results suggest that targeting some of these proteins (TOX2 in particular) might provide interesting opportunities for immunotherapy in patients with cHL.